BSC-1 非洲綠猴腎細胞
Catalogue No.: C272
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%EMEM(MEM+NEAA)+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

(pembrolizumab) showed limited antitumor activity with an objective response rate (ORR) of 3.7% in 107 patients with advanced well-differentiated neuroendocrine tumors (NET) (6). The multicohort, phase 1 KEYNOTE-028 study in patients with PD-L1-positive NET treated with pembrolizumab demonstrated an ORR of 12.0% inpatients with carcinoid and 6.3% in patients with well-differentiated or moderately-differentiated pancreatic NET (7). In addition, based on a phase II basket trial of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab)